Publications found:
73,128
Sort by:
MSL-KOL Engagement: Measuring Success
US$ 595.00
It’s difficult to quantify. Its role constantly changes. And despite all efforts to gain transparency, the field of medical science liaison (MSL) remains an elusive—seemingly immeasurable—yet undeniab...
December 2011
26 pages
US Glucose Monitoring Market Analysis
US$ 1,000.00
The US has a dominant share in the global diabetes market with 90-95% of the diabetic patients in the country suffering from type-II diabetes. Factors like, high prevalence of diabetes, rising aging p...
November 2011
55 pages
Competitor Analysis: Anti-Infective Antibodies
US$ 1,086.00
Product description The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of ...
November 2011
160 pages
GALAPAGOS - Waiting for Santa!
US$ 90.00
... , please read our report released on 22nd November on GLPG titled “Waiting for Santa”!
November 2011
3 pages
PHARMASSET - "IFN-free Oral Option" for HCV- Sharing the Big Pie!
US$ 140.00
Pharmasset (VRUS) may enjoy the first mover advantage in the race to offer the first “IFN free all oral option” to HCV pts. However the window ... read our report released on Nov. 16th, 2011 on VRUS titled “IFN-free Oral Option” for HCV- Sharing the Big Pie!
November 2011
9 pages
SUN PHARMA - A structural improvement at play
US$ 140.00
Sun’s Q2 FY12 result was much higher than our and street’s ... after acquisition of 100% stake. We thus rate Sun Pharma as our top pick in the large cap India pharma. We will change our estimate later to incorporate ...
November 2011
7 pages
Lemtrada: Co-primary Endpoints Met in CARE MS II: Ready for filing
US$ 90.00
... alert on Sanofi, after today’s announcement of superior clinical data on Lemtrada from CARE MS II (The Comparison of Alemtuzumab and Rebif Efficacy in ... Sclerosis) study. A cross trial comparisons (Table 1) suggest that Lemtrada should dominate as the most efficacious treatment option, and Ocrelizumab ...
November 2011
4 pages
CADILA HEALTHCARE - Still Carrying The Burden of The High Base Last Year
US$ 140.00
Cadila’s Q2 FY12 result was below our estimate (adjusted to ... for muted growth in markets like India and Emerging Markets, we believe that the growth is still impacted due to the high ... the markets. We thus do not see any structural issues with Cadila. In addition, USFDA approval of its Baddi facility comes as a ...
November 2011
5 pages
DISHMAN - Downward Guidance Revision – No More An Exception
US$ 140.00
Dishman once again reported quarterly result much below our and ... . Thus debt repayment can happened only through asset sale. We revise our FY 12 earnings estimates down by 28%. Consequently we cut our target price ...
November 2011
5 pages
RANBAXY - Moderate Improvement In Base Business
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after Q3 CY11 result that was largely in line with our ... the low base of EBITDA margin, the improvement was expected to be slightly higher especially as Ranbaxy has shut down most of its loss making ...
November 2011
6 pages
LUPIN - Margin Pressure Highlight The Weakness of US Portfolio
US$ 140.00
... on Lupin after its Q2FY12 result that was largely in line with our estimates. Ex-Medicis milestone income, sales growth (up 17%) and gross margin ... of one per quarter and (3) Suprax growing by 43% Y-o-Y. We believe all these highlights (1) the dependence on generic Lotrel (2) increased sales force expense for ...
November 2011
6 pages
TOWA - Performance Will Outcast New ‘Mid Term Plan’
US$ 140.00
In Towa’s MTP announcement, it has projected single digit revenue growth and assumed there will not be any ‘New Major Reform’ by Govt to enhance ... in dispensing fee and incentives to doctors will boost Towa’s revenue (as 90%+ its revenue from these two segments), 2) Towa management is taking the right decision ...
November 2011
7 pages
Interacting with KOLs: Fulfilling Current Unmet Needs
US$ 995.00
The symbiotic relationship between key opinion leaders (KOLs) and the pharmaceutical industry is dynamic and ever-changing. But while the industry knows what it wants from KOLs, what do KOLs need from...
November 2011
41 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
... ) wave to treat HCV the race to offer the first “IFN free all oral option” seems to have begun. Preliminary data from Abbott’s PhII trial ... ’11 is challenging Pharmasset (VRUS) multiprong approach. For more details, please read our report released on Oct. 24th, 2011 on VRUS titled “IFN-free Oral Option” for ...
October 2011
4 pages
Payer Agreements: Splitting the Risk
US$ 695.00
Budgets are tight. Payer funding for new products is dwindling. And for pharmaceutical companies, market access is more and more difficult to attain.Across the UK, the US, Canada, Australia and parts...
October 2011
41 pages
China Medical Information System Industry Report, 2011
US$ 1,500.00
Status quo of China medical services, including medical resource allocation, medical efficiency and main existing problems;
Policies, construction and investment of China medical information...
October 2011
52 pages
Brazil Healthcare Market Analysis
US$ 1,000.00
Backed by several factors, such as strong government support and high healthcare demand amongst others are propelling the Brazilian healthcare market to grow at a fast pace. In fact, Brazil can be cla...
October 2011
75 pages
Health Technology Assessment (HTA): a European perspective
US$ 995.00
The bottom line: For payers facing tough financial crunches across Europe, Health Technology Assessment (HTA) is becoming increasingly important. Not only is HTA influencing reimbursement, it is havin...
October 2011
48 pages
Spinal Surgery: Market Research Report
US$ 4,500.00
... report analyzes the worldwide markets for Spinal Surgery in US$ Million by the following Product Segments: Spinal Fusion Devices, Spinal Fixation Devices, Artificial ... Plc, SpineVision, Stryker Corporation, Synthes Inc., and Zimmer Spine Inc. Market data and analytics are derived from primary and secondary ...
October 2011
411 pages
Autoimmune Disease Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Autoimmune Disease Therapeutics in US$ Million by the following Therapeutic Class: Rheumatoid Arthritis (Biologics), Multiple ... 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 112 companies including many key and niche ...
October 2011
749 pages
Multiple Myeloma Therapeutics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Multiple Myeloma Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, ... , Inc., Millennium Pharmaceuticals, Seattle Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived from primary and secondary ...
October 2011
595 pages
Wound Care Products: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Wound Care Products in US$ Million. The major Product Segments analyzed are Traditional {Wound Management Products ( ... through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 200 companies including many key and niche ...
October 2011
1027 pages
Coronary Stents: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Coronary Stents in US$ Million and Thousand Units by the following Product Segments: Bare Metal ... Corporation, Medtronic, Inc., Medtronic Cardiovascular, Inc., OrbusNeich, and Terumo Europe N.V. Market data and analytics are derived from primary and secondary ...
October 2011
396 pages
Ambulatory and Bathroom Aids: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Ambulatory and Bathroom Aids in US$ Million and Thousand Units by the following Product Segments: ... Ltd., Rebotec Rehabilitationsmittel GmbH, Sunrise Medical, and Thomas Fetterman, Inc. Market data and analytics are derived from primary and secondary research. ...
October 2011
654 pages
Blood Glucose Meters And Strips: Market Research Report
US$ 4,500.00
... for Blood Glucose Meters and Strips in US$ Million by the following Product Segments: Blood Glucose Strips, and Blood Glucose Meters. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. ...
October 2011
446 pages
CIPLA, Para IV Upside To Continue: Its Lexapro After Zyprexa
US$ 350.00
... of $1b) under 180-day exclusivity starting 14 March 2012. Cipla remained an active partner to Ivax (now Teva) by developing ... -day exclusivity. Thus Cipla too will share the upsides from the exclusivity. We expect Cipla to gain $50m ... will start accruing immediately after the upside from Zyprexa API supply to Teva ...
October 2011
3 pages
DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall!
US$ 140.00
Recent failures of Edoxaban’s key competitor factor-Xa inhibitors from Japan - YM 150 (Astellas) and TAK-442 (Takeda), the closest candidate in Japan now is Xarelto ... years away from hitting the market. Edoxaban is the first and only approved factor-Xa inhibitor in Japan for prevention of VTE, though Japanese ...
September 2011
4 pages
ROCHE, GLAXOSMITHKLINE - Exciting Data on TDM1 - Will Keep Competition at Bay
US$ 140.00
... months compared to Herceptin + docetaxel (14.2 m vs. 9.2 m- Table 1). The safety data as well, is very convincing as T-DM1 cut Grade 3 or more adverse effects ... 50% (46.4% vs. 89.4%). With T-DM1 and pertuzumab arrows in its quiver, Roche is well poised to sustain its breast cancer franchise beyond Herceptin ...
September 2011
4 pages
Observing Patients Online: the changing face of research
US$ 595.00
For years, patients have shouted to be heard. But as online patient communities, chat rooms and forums have gained popularity—and political clout—their voices are resonating.
Now being used t...
September 2011
47 pages
The 2011 Global Orthopedics Market Dynamics and Trends
US$ 1,480.00
... categories. In addition, the report presents a concise review of the major U.S. and international trends with potentially significant impact on the orthopedics market during the next five years, including industry consolidation, market globalization, environmental regulations, etc. The analysis of major ...
September 2011
53 pages
The European Orthopedics Market: Strategic Assessments of Leading Suppliers
US$ 7,600.00
The report provides strategic overview of the European orthopedics market, including forecasts for major market segments and product categories. In addition, ... of the major trends with potentially significant impact on the European orthopedics market during the next five years, including industry consolidation ...
September 2011
620 pages
The US Orthopedics Market: Strategic Assessments of Leading Suppliers
US$ 7,600.00
The report provides a strategic overview of the US orthopedics market, including forecasts for major market segments and product categories. In addition, the report presents a concise review of the major trends with potentially significant impact on the US ...
September 2011
620 pages
Vertex - Near Term Positive Long Term Neutral
US$ 140.00
... therapy area is heating up, Vertex (VRTX) will continue to have the edge for at least 3yrs. We expect most of the near term milestones related for ... read our report released on 23th September, 2011 on VRTX titled “Near Term Positive Long Term Neutral”.
September 2011
5 pages
